Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KDR Q472H |
| Therapy | unspecified VEGFR2 antibody |
| Indication/Tumor Type | melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR Q472H | melanoma | sensitive | unspecified VEGFR2 antibody | Preclinical | Actionable | In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613). | 26631613 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26631613) | Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. | Full reference... |